Cline Christopher R. (CIK 1943192) reported 26 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-17). Recent activity: Buy TVTX (20,000 shares), Sell TVTX (27,473 shares), Sell TVTX (20,735 shares), Sell TVTX (1,900 shares), Sell TVTX (400 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Buy | 20,000 | $348,800 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 27,473 | $1.7M |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 20,735 | $1.3M |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 1,900 | $121,004 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 400 | $26,124 |
| 2026-09-03 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 642 | $42,610 |
| 2026-05-06 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Buy | 4,250 | $0 |
| 2026-05-06 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 2,181 | $101,744 |
| 2026-05-06 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 310 | $13,624 |
| 2026-04-15 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 7,239 | $303,531 |
| 2026-04-15 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 65 | $1,875 |
| 2026-04-15 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 9 | $370 |
| 2026-04-15 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Buy | 14,000 | $0 |
| 2026-04-15 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 1,014 | $43,207 |
| 2026-02-05 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 1,635 | $52,549 |
| 2026-02-05 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 110 | $3,619 |
| 2026-02-03 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Buy | 28,130 | $0 |
| 2026-02-03 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 7,242 | $232,613 |
| 2025-12-03 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Buy | 20,000 | $324,600 |
| 2025-12-03 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 20,000 | $700,200 |
| 2025-09-05 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 454 | $8,263 |
| 2025-09-05 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 119 | $2,345 |
| 2025-08-28 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 470 | $8,136 |
| 2025-05-05 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Buy | 4,920 | $0 |
| 2025-05-05 | Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | Sell | 1,784 | $37,553 |
来源：SEC Form 4 申报文件 · 截至 2026-09-17